We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Current-Tunneling Measurements Analyze Single DNA Molecules

By LabMedica International staff writers
Posted on 09 Jul 2018
A team of Japanese genomics researchers has devised a method for cancer diagnosis, which is based on the analysis of single molecules of DNA without the need for chemical modification or amplification.

Cancer can be diagnosed by identifying DNA and microRNA base sequences that have the same base length yet differ in a few base sequences, if the abundance ratios of these slightly deviant base sequences can be determined. More...
However, such quantitative analyses cannot be performed using the current DNA sequencers.

In this regard, investigators at Osaka University (Japan) used current-tunneling measurements to determine the entire base sequences of four types of DNA corresponding to the let-7 microRNA, which is a 22-base cancer marker.

The tunneling currents flowing through single molecules were measured by gold electrodes – maintained at a distance of 0.75 nanometers from each other, equivalent to the size of a DNA base molecule – using a mechanically controllable break-junction. Single-molecule signals were obtained in forms of current spikes, whose height represented the electron transport through the molecule. Since this method measured single molecules, it did not require chemical modification of DNA or amplification by PCR.

As the method measured individual DNA molecules, two or more base sequences could be determined by measuring a solution of DNA molecules with two or more types of base sequences. Furthermore, since this method could count the number of DNA molecules that contained a specific base sequence, quantitative analysis could detect the base sequences and determine their frequency.

"Because the single-molecule sequencing method detects differences in the electronic states of molecules in terms of single-molecule conductances, it may also be applied to the analysis of microRNA and RNA molecules that include four base molecules and peptides that include 20 kinds of amino acids," said senior author Dr. Masateru Taniguchi, a professor in the institute of scientific and industrial research at Osaka University. "Also, as the method can detect chemically modified base molecules and amino acids, it represents a substantive step toward realizing personalized genomic diagnosis of cancer and other diseases."

The current-tunneling method was described in a paper published in the June 4, 2018, online edition of the journal Scientific Reports.

Related Links:
Osaka University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.